S. Leucht, H. Fennema, R. R. Engel, M. Kaspers-janssen, P. Lepping et al., What does the MADRS mean? Equipercentile linking with the CGI using a company database of mirtazapine studies, Journal of Affective Disorders, vol.210, pp.287-93, 2017.

M. Fedgchin, M. Trivedi, and E. J. Daly, Efficacy and Safety of Fixed-Dose Esketamine Nasal Spray Combined With a New Oral Antidepressant in Treatment-Resistant Depression: Results of a Randomized, Double-Blind, Active-Controlled Study (TRANSFORM-1), International Journal of Neuropsychopharmacology, vol.22, issue.10, pp.616-646, 2019.

V. Popova, E. J. Daly, and M. Trivedi, Efficacy and Safety of Flexibly Dosed Esketamine Nasal Spray Combined With a Newly Initiated Oral Antidepressant in Treatment-Resistant Depression: A Randomized Double-Blind Active-Controlled Study, Am J Psychiatry, vol.176, issue.6, pp.428-466, 2019.

R. Ochs-ross, E. J. Daly, and Y. Zhang, Efficacy and Safety of Esketamine Nasal Spray Plus an Oral Antidepressant in Elderly Patients With Treatment-Resistant Depression-TRANSFORM-3. The American journal of geriatric psychiatry : official journal of the American Association for Geriatric Psychiatry, 2019.

C. Gastaldon, D. Papola, G. Ostuzzi, and C. Barbui, Esketamine for treatment resistant depression: a trick of smoke and mirrors? Epidemiology and psychiatric sciences, vol.29, p.79, 2019.